Marker Therapeutics, Inc. — Director's Dealing 2004

Feb 17, 2004

SEC Form 5 — Annual Statement of Changes in Beneficial Ownership

Issuer: GENEMAX CORP (GMXX)
CIK: 0001094038
Period of Report: 2003-12-31

Reporting Person: ATKINS GRANT (Director, Chief Financial Officer)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2003-12-31	Common Stock $0.00 par value	A	0	—	Acquired	0	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2003-12-16	Stock Options	$0.50	A	250000	Acquired	2011-12-16	Common Stock (250000)	Direct

Footnotes

F1: Granted in accordance with the terms and provisions of the Stock Option Plan dated December 16, 2003, in consideration of services and duties performed.